| Autor: |
Wallace, Gerald E., Tjoelker, Madeleine, Bartley, Kaitlyn, Henson, John W., Wallace, Gerald C |
| Zdroj: |
Current Treatment Options in Oncology; Sep2021, Vol. 22 Issue 9, p1-16, 16p |
| Abstrakt: |
Opinion Statement: Nervous system tumors arising in the setting of monogenic, hereditary cancer predisposition syndromes are unique in that the initiating genetic event in tumor formation is known. This knowledge provides a powerful treatment approach if the alteration or pathway can be targeted with a therapeutic agent. A reasonable argument can be made for the use of targeted agents in these tumor patients, even though many of them have FDA approval only for other tumor types. It is our practice to use and employ targeted therapy when standard treatments have failed or represent an unattractive option. Over time, however, targeted therapies will likely become first-line options. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Full text from SpringerLink